ClariVest Asset Management LLC purchased a new stake in NeoGenomics Inc. (NASDAQ:NEO) during the second quarter, Holdings Channel reports. The firm purchased 80,200 shares of the company’s stock, valued at approximately $644,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in NEO. Falcon Point Capital LLC raised its position in shares of NeoGenomics by 12.5% in the second quarter. Falcon Point Capital LLC now owns 209,538 shares of the company’s stock valued at $1,685,000 after buying an additional 23,216 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of NeoGenomics by 14,127.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 142,276 shares of the company’s stock valued at $959,000 after buying an additional 141,276 shares during the last quarter. Fox Run Management L.L.C. bought a new position in NeoGenomics during the second quarter worth $171,000. Emerald Advisers Inc. PA bought a new position in NeoGenomics during the second quarter worth $2,413,000. Finally, Nicholas Investment Partners LP raised its position in NeoGenomics by 45.3% in the first quarter. Nicholas Investment Partners LP now owns 303,810 shares of the company’s stock worth $2,048,000 after buying an additional 94,665 shares in the last quarter. Institutional investors and hedge funds own 77.20% of the company’s stock.
Shares of NeoGenomics Inc. (NASDAQ:NEO) traded up 1.23% during mid-day trading on Friday, reaching $7.38. The company had a trading volume of 448,785 shares. The company has a 50 day moving average price of $8.05 and a 200 day moving average price of $8.15. NeoGenomics Inc. has a one year low of $5.49 and a one year high of $9.54. The company’s market capitalization is $574.85 million.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01. The company had revenue of $63.10 million for the quarter, compared to the consensus estimate of $61.07 million. NeoGenomics had a positive return on equity of 3.18% and a negative net margin of 3.76%. The firm’s quarterly revenue was up 159.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.01 EPS. On average, analysts anticipate that NeoGenomics Inc. will post $0.13 EPS for the current year.
A number of research firms have recently weighed in on NEO. Craig Hallum restated a “buy” rating on shares of NeoGenomics in a report on Saturday, July 9th. BTIG Research lowered NeoGenomics from a “buy” rating to a “neutral” rating in a report on Wednesday, July 27th. Benchmark Co. raised their target price on NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, July 27th. Zacks Investment Research lowered NeoGenomics from a “buy” rating to a “hold” rating in a report on Wednesday, September 28th. Finally, Raymond James Financial Inc. began coverage on NeoGenomics in a report on Thursday, September 8th. They issued an “outperform” rating and a $10.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $10.41.
In related news, insider Maher Albitar sold 60,075 shares of the company’s stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $8.23, for a total value of $494,417.25. Following the sale, the insider now owns 165,375 shares in the company, valued at approximately $1,361,036.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.20% of the stock is owned by corporate insiders.
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.